Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).

by Laurence Peiperl, Cecilia Morgan, Zoe Moodie, Hongli Li, Nina Russell, Barney S Graham, Georgia D Tomaras, Stephen C De Rosa, M Juliana McElrath, NIAID HIV Vaccine Trials Network
Published 2010-10-01

Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.

by Beryl A Koblin, Martin Casapia, Cecilia Morgan, Li Qin, Zhixue Maggie Wang, Olivier D Defawe, Lindsey Baden, Paul Goepfert, Georgia D Tomaras, David C Montefiori, M Juliana McElrath, Lilian Saavedra, Chuen-Yen Lau, Barney S Graham, NIAID HIV Vaccine Trials Network
Published 2011-01-01

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia...

by Susan P Buchbinder, Nicole A Grunenberg, Brittany J Sanchez, Kelly E Seaton, Guido Ferrari, M Anthony Moody, Nicole Frahm, David C Montefiori, Christine M Hay, Paul A Goepfert, Lindsey R Baden, Harriet L Robinson, Xuesong Yu, Peter B Gilbert, M Juliana McElrath, Yunda Huang, Georgia D Tomaras, HIV Vaccine Trials Network (HVTN) 094 Study Group
Published 2017-01-01

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine i...

by Marnie L Elizaga, Shuying S Li, Nidhi K Kochar, Gregory J Wilson, Mary A Allen, Hong Van N Tieu, Ian Frank, Magdalena E Sobieszczyk, Kristen W Cohen, Brittany Sanchez, Theresa E Latham, David K Clarke, Michael A Egan, John H Eldridge, Drew Hannaman, Rong Xu, Ayuko Ota-Setlik, M Juliana McElrath, Christine Mhorag Hay, NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team
Published 2018-01-01

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

by Gavin J Churchyard, Cecilia Morgan, Elizabeth Adams, John Hural, Barney S Graham, Zoe Moodie, Doug Grove, Glenda Gray, Linda-Gail Bekker, M Juliana McElrath, Georgia D Tomaras, Paul Goepfert, Spyros Kalams, Lindsey R Baden, Michelle Lally, Raphael Dolin, William Blattner, Artur Kalichman, J Peter Figueroa, Jean Pape, Mauro Schechter, Olivier Defawe, Stephen C De Rosa, David C Montefiori, Gary J Nabel, Lawrence Corey, Michael C Keefer, NIAID HIV Vaccine Trials Network
Published 2011-01-01

Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.

by Gemma Hancock, Hongbing Yang, Elisabeth Yorke, Emma Wainwright, Victoria Bourne, Alyse Frisbee, Tamika L Payne, Mark Berrong, Guido Ferrari, Denis Chopera, Tomas Hanke, Beatriz Mothe, Christian Brander, M Juliana McElrath, Andrew McMichael, Nilu Goonetilleke, Georgia D Tomaras, Nicole Frahm, Lucy Dorrell
Published 2015-02-01

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.

by Zoe Moodie, Stephen R Walsh, Fatima Laher, Lucas Maganga, Michael E Herce, Sarita Naidoo, Mina C Hosseinipour, Craig Innes, Linda-Gail Bekker, Nicole Grunenberg, Philipp Mann, Chenchen Yu, Allan C deCamp, Maurine D Miner, Nicole L Yates, Jack Heptinstall, Nonhlanhla N Mkhize, One Dintwe, Nicole Frahm, Kristen W Cohen, Mary Allen, Julia Hutter, Ralf Wagner, Giuseppe Pantaleo, M Juliana McElrath, Georgia D Tomaras, Lynn Morris, David C Montefiori, Erica Andersen-Nissen, Glenda E Gray, Peter B Gilbert, James G Kublin, NIAID HVTN 100 and HVTN 111 trial teams
Published 2020-05-01

Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.

by Michael Vaine, Shixia Wang, Qin Liu, James Arthos, David Montefiori, Paul Goepfert, M Juliana McElrath, Shan Lu
Published 2010-11-01